Trending news

Kathy Williams, Ph.D., a partner in Nutter’s Intellectual Property Department and chair of the firm’s Life Sciences group, weighed in on how the Supreme Court decision in Amgen v. Sanofi will broadly affect innovation of antibody therapies in BioCentury. In the article, “Innovation at stake in PCSK9 patent battle extends beyond antibodies,” Kathy pointed out that it’s becoming more common for antibody claims to be limited to sequences of specific compounds. However, genus claims are still granted, with Kathy explaining, “If one discovers a new antigen or a new epitope that has some function, the way it has gone is that you, in fact, get a genus claim.”